The impaired response inhibition and salience attribution (iRISA) model proposes that
impaired response inhibition and salience attribution underlie drug seeking and taking. To …

Psychostimulants, including amphetamines and methylphenidate, are first-line
pharmacotherapies for individuals with attention-deficit/hyperactivity disorder (ADHD). This …

A growing preclinical and clinical body of work on the effects of chronic drug use and drug
addiction has extended the scope of inquiry from the putative reward-related subcortical …

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder with a
complex symptomatology, and core symptoms as well as functional impairment often persist …

Despite substantial investments by government, philanthropic, and commercial sources over
the past several decades, traumatic brain injury (TBI) remains an unmet medical need and a …

The use of prescription stimulants to enhance healthy cognition has significant social,
ethical, and public health implications. The large number of enhancement users across …

Rationale Psychostimulants, including methylphenidate (MPH), are the mainstay of
pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) in adults. Even though …

Methylphenidate (MPH), a stimulant drug with dopamine and noradrenaline reuptake
inhibition properties, is mainly prescribed in attention deficit hyperactivity disorder, is …

Background Cocaine dependence is a severe disorder for which no medication has been
approved. Like opioids for heroin dependence, replacement therapy with psychostimulants …

Importance Individuals with cocaine use disorder (CUD) have difficulty monitoring ongoing
behavior, possibly stemming from dysfunction of brain regions mediating insight and self …